Xenetic Biosciences Inc
XBIO3.010USD
-0.205-6.38%
Market hours （ET）Quotes delayed by 15 min
4.64MMarket Cap
LossP/E TTM
More Details of Xenetic Biosciences Inc Company
Xenetic Biosciences, Inc. is a biopharmaceutical company. The Company is focused on advancing immune-oncology technologies addressing hard to treat cancers. The Company's DNase platform is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in cancer progression. It is focused on advancing the development of its DNase platform toward a first-in-human, multicenter, dose escalation and dose-expansion study of IV rhDNase I in subjects with locally advanced or metastatic solid tumors. Its systemic DNase program is initially targeting multi-billion-dollar indications including pancreatic cancer, which includes pancreatic ductal adenocarcinoma (PDAC), colorectal carcinoma (CRC) and other gastrointestinal cancers. These are all cancer indications with significant unmet need, and with opportunities for substantial improvement of the available therapeutic options.
Company Info
Ticker SymbolXBIO
Company nameXenetic Biosciences Inc
IPO dateNov 07, 2016
CEOMr. James F. (Jim) Parslow
Number of employees2
Security typeOrdinary Share
Fiscal year-endNov 07
Address945 Concord St.
CityFRAMINGHAM
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code01701
Phone17817787720
Websitehttps://www.xeneticbio.com/
Ticker SymbolXBIO
IPO dateNov 07, 2016
CEOMr. James F. (Jim) Parslow
Company Executives
Name
Name/Position
Position
Shareholding
Change
Dr. Dmitry Dmitrievich Genkin, M.D.
Dr. Dmitry Dmitrievich Genkin, M.D.
Director
Director
68.46K
--
Mr. Moshe Mizrahy
Mr. Moshe Mizrahy
Director
Director
--
--
Dr. Alexey Vinogradov
Dr. Alexey Vinogradov
Independent Director
Independent Director
--
--
Ms. Jenene Thomas
Ms. Jenene Thomas
Investor Relations
Investor Relations
--
--
Mr. James F. (Jim) Parslow
Mr. James F. (Jim) Parslow
Interim Chief Executive Officer, Chief Financial Officer, Corporate Secretary
Interim Chief Executive Officer, Chief Financial Officer, Corporate Secretary
--
--
Dr. Grigory G. Borisenko, Ph.D.
Dr. Grigory G. Borisenko, Ph.D.
Independent Director
Independent Director
--
--
Mr. Firdaus Jal Dastoor
Mr. Firdaus Jal Dastoor
Independent Director
Independent Director
--
--
Dr. Roger D. Kornberg, Ph.D.
Dr. Roger D. Kornberg, Ph.D.
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Dmitry Dmitrievich Genkin, M.D.
Dr. Dmitry Dmitrievich Genkin, M.D.
Director
Director
68.46K
--
Mr. Moshe Mizrahy
Mr. Moshe Mizrahy
Director
Director
--
--
Dr. Alexey Vinogradov
Dr. Alexey Vinogradov
Independent Director
Independent Director
--
--
Ms. Jenene Thomas
Ms. Jenene Thomas
Investor Relations
Investor Relations
--
--
Mr. James F. (Jim) Parslow
Mr. James F. (Jim) Parslow
Interim Chief Executive Officer, Chief Financial Officer, Corporate Secretary
Interim Chief Executive Officer, Chief Financial Officer, Corporate Secretary
--
--
Dr. Grigory G. Borisenko, Ph.D.
Dr. Grigory G. Borisenko, Ph.D.
Independent Director
Independent Director
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Fri, May 16
Updated: Fri, May 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
CLS Therapeutics, Ltd.
9.56%
Genkin (Dmitry Dmitrievich)
4.44%
PJSC Pharmsynthez
3.42%
Renaissance Technologies LLC
1.74%
Susquehanna International Group, LLP
1.65%
Other
79.19%
Shareholders
Shareholders
Proportion
CLS Therapeutics, Ltd.
9.56%
Genkin (Dmitry Dmitrievich)
4.44%
PJSC Pharmsynthez
3.42%
Renaissance Technologies LLC
1.74%
Susquehanna International Group, LLP
1.65%
Other
79.19%
Shareholder Types
Shareholders
Proportion
Corporation
12.99%
Individual Investor
6.07%
Investment Advisor
4.32%
Hedge Fund
2.86%
Investment Advisor/Hedge Fund
0.76%
Research Firm
0.02%
Other
72.99%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
30
416.60K
27.01%
+12.07K
2025Q1
36
412.01K
26.72%
-933.00
2024Q4
36
393.92K
25.54%
+18.73K
2024Q3
34
352.79K
22.89%
+17.12K
2024Q2
31
318.94K
20.69%
-45.34K
2024Q1
31
323.67K
21.00%
-37.99K
2023Q4
34
303.91K
19.80%
+10.04K
2023Q3
37
285.57K
18.68%
-66.63K
2023Q2
36
249.73K
16.47%
-88.82K
2023Q1
36
268.69K
17.72%
-79.20K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
CLS Therapeutics, Ltd.
147.50K
9.56%
--
--
Mar 31, 2025
Genkin (Dmitry Dmitrievich)
68.46K
4.44%
--
--
Mar 31, 2025
PJSC Pharmsynthez
52.80K
3.42%
--
--
Mar 31, 2025
Renaissance Technologies LLC
26.76K
1.74%
+1.21K
+4.75%
Mar 31, 2025
Susquehanna International Group, LLP
25.39K
1.65%
+9.53K
+60.09%
Mar 31, 2025
Vinogradov (Alexey Andreevich)
18.68K
1.21%
--
--
Mar 31, 2025
Citadel Advisors LLC
17.29K
1.12%
+3.91K
+29.22%
Mar 31, 2025
Sachetta, LLC
10.67K
0.69%
+3.29K
+44.70%
Mar 31, 2025
LGT Wealth Management Limited
11.00K
0.71%
--
--
Mar 31, 2025
Geode Capital Management, L.L.C.
10.95K
0.71%
-936.00
-7.87%
Mar 31, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
May 12, 2023
Merger
10<1
May 12, 2023
Merger
10<1
May 12, 2023
Merger
10<1
May 12, 2023
Merger
10<1
Date
Type
Ratio
May 12, 2023
Merger
10<1
May 12, 2023
Merger
10<1
May 12, 2023
Merger
10<1
May 12, 2023
Merger
10<1
